1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €7.77 (+198.85%). The median is €7.77 (+198.85%).
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | 0 | 100.00% |
| Net profit | -3.26M | 20.40% |
| EBITDA | -3.37M | 17.11% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €17.17M |
Number of shares | 6.32M |
52-week high/low | €10.49 - €2.18 |
| Dividends | No |
Beta | 0.26 |
P/E ratio | -0.51 |
PEG ratio | 0.00 |
P/B ratio | 0.14 |
P/S ratio | 2.66 |
Company profile
| Name | EVAXION BIOTECH SP.ADS/50 ADR |
| CEO | Helen Katrina Tayton-Martin |
| Employees | 46 |
Discover assets
Shareholders of EVAXION BIOTECH SP.ADS/50 ADR also invest in the following assets
